Return to search

John Ryan Joins Onset

John Ryan has joined Onset Ventures as a partner, with a focus on medical technology opportunities. He previously was with Panorama Capital, where he led the medical device practice. 

 

PRESS RELEASE

ONSET Ventures today announced that John Ryan has joined the firm as a partner. Ryan will work with the medical technology investing team.

“There continue to be substantial unmet basic medical needs globally and in the U.S.,” said Leslie Bottorff, ONSET managing director. “Moreover, the aging of the baby boomer population is providing additional high-growth opportunities for early stage medical device companies that bring unique solutions to their healthcare problems. John brings considerable experience in the sector, and we are pleased to add him to our investment team at such an opportune time.”

Ryan joins ONSET from Panorama Capital, a venture capital firm created by the venture capital team from JPMorgan Partners. At Panorama and JPMorgan Partners, Ryan led the firm's venture investing efforts in the medical device sector and was one of the founders of the firm's west coast life sciences practice. During that time, Ryan served on the boards of directors of CardioKinetix, FlowCardia, Innovative Spinal Technologies, Novasys Medical, and Powervision, among other companies. Before that, he was with Morgan Stanley Venture Partners where he also focused on medical technology investments and participated in investments in companies such as Intuitive Surgical (NASDAQ: ISRG), R2 Technologies (acquired by Hologic), and Rita Medical Systems (acquired by AngioDynamics). Earlier, Ryan worked with Morgan Stanley's Health Care Investment Banking Group where he focused on financing and M&A business for health-care focused clients globally. Ryan holds an M.B.A. from the Harvard Business School and a Bachelor of Science degree with high honors from the University of Colorado.

“Technological innovation and very creative entrepreneurs are enabling new medical technologies to fulfill previously unmet needs and, in many cases, provide more cost-effective therapeutic options,” said ONSET Managing Director Rob Kuhling. “With all this emerging opportunity, we are actively increasing our bandwidth to uncover and invest in the best of these ideas.”

ONSET sees particularly interesting opportunities are in neurostimulation, cardiac care, obesity treatment, orthopedics, and other markets. The firm's investments in the sector have included such key companies as Conceptus, Spinal Concepts, Enteromedics, Access Closure, Neuronetics, Embolic Protection, and others.

Ryan explained his reasons for joining the firm: “ONSET is one of the few venture firms that has, for more than 20 years, had a practice with an unwavering commitment to early stage medical technology investing. This expertise in working collaboratively with developing companies, and the firm's wide network and deep industry experience make ONSET an excellent partner for its portfolio companies. This is evidenced by the array of top-quality entrepreneurs that choose to work with ONSET repeatedly.”

According to Peter Edelstein, MD, President and CEO of Aragon Surgical, an ONSET portfolio company: “It's critical that venture capitalists bring more than just money at the early stage